Verrica Pharmaceuticals Analyst Price Targets - Benzinga

Verrica Pharmaceuticals Inc

VRCANASDAQ

Trade with Public

Trade with Public

$3.21

-0.14-4.18%

Ult. Agg.: Nov 2, 4:35 PM

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Opzioni Rapporto azionario

Verrica Pharmaceuticals Analyst Price Targets - Benzinga

Verrica Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Verrica Pharmaceuticals (VRCA).

Price Target Range — 7 Quarters

Analyst Consensus — 6 Analysts

4Buy

2Hold

Consensus RatingBuy# Analysts6Avg. Consensus PT$55Upside to Avg. PT+1621.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 26, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Assumes	Buy	$12
Dec 18, 2025	Brookline Capital	Kemp Dolliver	Upgrade	Hold→Buy	$17
May 14, 2025	Needham	Serge Belanger	Maintained	Hold	—
Apr 9, 2025	Needham	Serge Belanger	Maintained	Hold	—
Apr 8, 2025	HC Wainwright & Co.	Oren Livnat	Maintained	Neutral	—
Mar 12, 2025	Needham	Serge Belanger	Maintained	Hold	—
Dec 20, 2024	Needham	Serge Belanger	Maintained	Hold	—
Nov 6, 2024	HC Wainwright & Co.	Oren Livnat	Downgrade	Buy→Neutral	—
Nov 5, 2024	Needham	Serge Belanger	Maintained	Hold	—
Nov 5, 2024	RBC Capital	Gregory Renza	Downgrade	Outperform→Sector Perform	$110→$20
Oct 21, 2024	TD Cowen	Stacy Ku	PT Cut	Buy	$150→$100
Oct 4, 2024	RBC Capital	Gregory Renza	PT Cut	Outperform	$130→$110
Oct 3, 2024	Needham	Serge Belanger	Downgrade	Buy→Hold	$120
Oct 2, 2024	Brookline Capital	Kemp Dolliver	Downgrade	Buy→Hold	—
Aug 15, 2024	RBC Capital	Gregory Renza	PT Cut	Outperform	$140→$130
Aug 15, 2024	Needham	Serge Belanger	PT Cut	Buy	$160→$120
May 16, 2024	Needham	Serge Belanger	Maintained	Buy	$160
May 14, 2024	HC Wainwright & Co.	Oren Livnat	PT Raise	Buy	$130→$140
May 14, 2024	Needham	Serge Belanger	PT Raise	Buy	$80→$160
Apr 10, 2024	Needham	—	Maintained	Buy	$80

Analyst Ratings News

PRO
HC Wainwright & Co. Assumes Verrica Pharmaceuticals at Buy, Announces Price Target of $12

HC Wainwright & Co. analyst Raghuram Selvaraju assumes Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
Brookline Capital Upgrades Verrica Pharmaceuticals to Buy, Announces $17 Price Target

Brookline Capital analyst Kemp Dolliver upgrades Verrica Pharmaceuticals (NASDAQ:VRCA) from Hold to Buy and announces $17 price target.

Benzinga Newsdesk

PRO
Needham Reiterates Hold on Verrica Pharmaceuticalsto Hold

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) from Hold to Hold.

Benzinga Newsdesk

PRO
Needham Reiterates Hold on Verrica Pharmaceuticalsto Hold

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) from Hold to Hold.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Verrica Pharmaceuticalsto Neutral

HC Wainwright & Co. analyst Oren Livnat reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) from Neutral to Neutral.

Benzinga Newsdesk

PRO
Needham Reiterates Hold on Verrica Pharmaceuticalsto Hold

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) from Hold to Hold.

Benzinga Newsdesk